Global haemophilia market is expected to reach USD 23.99 billion by 2033, at a CAGR of 5.34% from 2024 to 2033. Global haemophilia market is witnessing a considerable growth owing to the growing prevalence of haemophilia across the globe. Ongoing improvements and developments have strengthened the healthcare sector, strengthening the healthcare infrastructure even in underdeveloped countries. Older people are more likely to suffer from haemophilia, which requires long-term care and treatment. Better diagnostics techniques are also being used, which diagnose haemophilia very accurately. Due to this, haemophilia can be managed by diagnosing it early and starting treatment at the right time. With the increasing digitalization, wearable technology can be used. With its help, real-time patient monitoring can be done so that changes in treatment can be made as needed.

Market Overview:

Haemophilia is considered generally an inherited bleeding disorder in which blood does not clot, or there is a problem in the clotting of blood. This can lead to spontaneous bleeding after a mere cut or bruise and even in the case of surgeries. Blood contains many proteins which are called clotting factors. This clotting factors are responsible for the clotting of blood. People who are suffering from haemophilia are either having low clotting factor VIII or low clotting factor IX. The severity of haemophilia depends on the level of clotting factors in the blood. Lower the level of clotting factors in the blood more will be the bleeding which could lead to serious health problems. In some cases, haemophilia shows symptoms late, or people develop this later in life like middle-aged and elderly person.  Women who have just given birth to a child or if she is in the later stage of pregnancy can also show symptoms. Such cases can be cured with proper treatment. People suffering from haemophilia should be careful as bleeding within joints can lead to chronic joint pain and disease, bleeding in the head can lead to seizures and paralysis, bleeding from vital organs can also be fatal if it can’t be stopped and lead to death. There are many types of Haemophilia. The two most common type of haemophilia is Haemophilia A, and Haemophilia B. Heamophilia A happens due to a lack of clotting factor VIII. Haemophilia B happens due to a lack of clotting factor IX. The best way for treatment is to replace the clotting factor. This way, blood start clotting. This replacement is done by infusion of factor concentrates. Currently, over 20,000 males are suffering from haemophila in US. Haemophilia A is four times more common compared to Haemophilia B. Half of the people suffering from Haemophilia are in serious form. According to the World Federation of Hemophilia record, 184,723 people were suffering from haemophilia in 2016.

Get an overview of this study by requesting a free sample

Market Dynamics:

Drivers

• Growing prevalence of haemophilia across the globe

According to the record 1 in every 5000 male birth is suffering from haemophilia, which prevents clotting of blood. In US every year 400 born babies are suffering from haemophilia. According to the World Federation of Hemophilia record, 184,723 people were suffering from haemophilia in 2016. According to WHO, there is higher chance of haemophilia in male when compared to women; this is due to sex linkage disorder. This is prevalent all across the globe. One of the record showed that 1/3rd of the diagnosed people have no family history for haemophilia.

• Increasing investment in R&D and new product development

Cryoprecipitate use is the best way of stopping haemophilia bleeding.  But the recent technology called factor concentrates is the greatest breakthrough in such cases. This factor concentrates diagnose the patient suffering from haemophilia with greater efficiency. This revolutionary technology has made the treatment of the patient very easy, and so is the life of the patient. One can be easily treated at home or at work. Also, the investment in R&D and the development of new technologies like gene therapy and non-factor replacement therapy are driving the market.

Restraints:

• High cost associated with haemophilia treatment

Haemophilia is connected with staggering direct costs from hospitalisations, outpatient visits, and drug treatments, as well as high indirect costs from diminished work productivity and absenteeism from work and school. Drugs are very expensive. Medications to treat haemophilia can cost up to an average of more than $270,000 annually per patient. In further complications, that yearly price tag can soar above $1 million. So this act as a restraint for haemophilia market.

Opportunities:

• Increasing popularity and demand for gene therapy

Advancement and introduction of new medications and technologies such as non-factor replacement therapy, extended half-life products, gene therapy, etc. will boost the growth of haemophilia treatment market growth in the near future. Gene therapy provides a potential phenotypic cure for haemophilia, yet the cost of this novel treatment is high, tempering enthusiasm and raising questions regarding cost vs benefit.

Segmentation Analysis:

The global Hemophilia market has been segmented based on disease type, therapy, product type and regions.

• Disease Type segment include haemophilia A, haemophilia B and others. The haemophilia A segment held a substantial industry share of over 61.21% in 2023. Type A has been observed to be four times more widespread than type B. The pharmaceutical industries are flooded with drugs for the treatment of type A.  However, over the forecast period, the sector is expected to witness the fastest growth for type B-based medication, as showed there is a rise in the number of people being diagnosed with type B and by the increasing efforts to tackle it.
• The therapy segment includes replacement therapy, gene therapy and others. Replacement therapy segment is accounted for the largest market share of around 76.23% in 2023. This is because replacement therapy is the first treatment recommended for patients suffering from moderate to severe haemophilia. Also, the investment in R&D would lead to the use of new drugs in replacement therapy. This is also driving the segment. Gene therapy is a growing field which focuses on identifying the defective DNA bases and then reinstating it with functional ones. Hence, this segment is anticipated to provide the most lucrative opportunities for the current players over the forecast period.
• The product type segment includes Recombinant Coagulation Factor Concentrates, Plasma-derived Coagulation Factor Concentrates and Others. Recombinant Coagulation Factor Concentrates segment accounted for the highest market share of 57.51% and was valued USD 8.20 Billion in 2023. This is due to the fact that it has increased the safety in replacement therapy that has enhanced the quality of living for Hemophilia suffering patient. That’s why it has become the most preferred treatment. Moreover, the increase in the production of recombinant factor concentrates would provide a better opportunity for the market in the future.

Regional segmentation analysis:

The regions analyzed for the Haemophilia market include North America, Europe, South America, Asia Pacific, and the Middle East and Africa. North America region is accounted for the largest market share of 44.67% of the market in 2023.

Check the geographical analysis of this market by requesting a free sample

• High prevalence together with a rising inclination toward prophylaxis treatment, is predicted to be the preliminary drivers of this growth. According to the annual global survey, of WFH, it is estimated that about 64.0% of the patients in the U.S. have chosen for prophylaxis treatment, thereby propelling the growth.
• However, over the forecast period, Asia-Pacific will show the fastest growth. Rise in the identification of cases in countries such as India, Indonesia, Japan, and Malaysia along with increasing use of therapies for factor VIII (type A) and IX (type B) deficiency are the vital impact rendering drivers.

Competitive Analysis:

The key players are now concentrating on implementing strategies such as adopting new technology, product innovations, mergers & acquisitions, joint venture, alliances and partnerships to improve their market position in the global Haemophilia industry.

For instance, in June 2016, Shire Plc acquired the Baxalta in June 2016. This is done to further expand the existent product portfolio of the company.

For instance, in March 2016, Baxalta filed an application for marketing authorization of Adynovi (Adynovate in the U.S.) with the EMA, which then was under the regulatory evaluation in Switzerland.

List of Key Market Players:

• Baxalta
• CSL Behring
• Pfizer, Inc.
• Bayer Healthcare
• BioMarin Pharmaceutical, Inc.
• Biogen
• Chugai Pharmaceutical Co.
• Novo Nordisk
• Shire Plc.
• Baxter International, Inc
• Hospira Inc.

Key Target Audience

• Hospitals
• Clinics
• Government Authorities
• Research Organization

Report Description:

• Global haemophilia Market, Industry Analysis, Trends, Analysis and Forecast, 2024 to 2033 is a forthcoming/imminent research report which is to be published by The Brainy Insights.
• 2023 is considered as the base year of the report. 2020 to 2022 are considered as the historic years and 2024 to 2033 are the forecast years. The global XX market is based on revenue (USD Million/Billion), volume and price. The report incorporates the market study on the basis of revenue, and volume. The study covers the market share revenue/market share/volume for each of the segments, regions and countries catering to global haemophilia market. The regions analyzed for the market are Europe, Asia Pacific, North America, South America and Middle East & Africa. Furthermore, the regions are further analyzed at the country level.
• The report encompasses with the relative data & information, which have been validated by the leading industry professionals and experts all across the globe. The research report also delivers an outline of the attractiveness of disease type, therapy, product type and regions which are deduced and formulated on the basis of their growth rate (CAGR), market size, and attractiveness by analyzing the present and future prospects to fathom market growth and development in future.
• The report illustrates the detailed (both quantitative and qualitative) analysis of historical data, revenues, key developments, along with the crucial strategies adopted by key organizations catering to global haemophilia market.  This offers vital and in depth insights in order to depict the overall market scenario.
• The report offers the detailed study for the company profiles of key organizations operating in the global haemophilia market and a comparative assessment based on their product offering, business overviews, geographic presence, business strategies, segment market share, product development & innovations, recent developments, joint venture, partnerships, mergers & acquisitions, strategic alliances, SWOT analysis, and key financial information. This helps in evaluating the overall competition present in the market scenario. 
• The report provides an elaborative assessment of the porter’s five forces analysis coupled with SWOT analysis so as to provide business related data and information’s. Porter’s five forces model is analyzed to understand the overall competitive scenario that is prevailing in the market. Additionally, the SWOT analysis identifies both the positive and negative attributes of the market development which influences the company growth and development in order to sustain and survive in the long run.
• Along with that, the report also focuses on the market related driving factors, growth limitations (restraints), potential industry opportunities, significant trends and development which acts as a key potential for the investors. 
• Potential growth prospects along with the penetration rate analysis of the products (market related i.e., global haemophilia market) is covered in order to comprehend the adoption rate and evaluate the market size.